Disruptions Suppress M&A and Financing (ICIS Chemical Business (May 20-26, 2022 issue)
Young & Partners dissects how disruptions and uncertainties are depressing M&A, equity prices and debt financings
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)
Young & Partners covers the changes the chemical industry is facing now and will face in the future
Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)
Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook
Disruptions Suppress M&A and Financing (ICIS Chemical Business (May 20-26, 2022 issue)
Young & Partners dissects how disruptions and uncertainties are depressing M&A, equity prices and debt financings
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)
Young & Partners covers the changes the chemical industry is facing now and will face in the future
Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)
Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook
Disruptions Suppress M&A and Financing (ICIS Chemical Business (May 20-26, 2022 issue)
Young & Partners dissects how disruptions and uncertainties are depressing M&A, equity prices and debt financings
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)
Young & Partners covers the changes the chemical industry is facing now and will face in the future
Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)
Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook
Disruptions Suppress M&A and Financing (ICIS Chemical Business (May 20-26, 2022 issue)
Young & Partners dissects how disruptions and uncertainties are depressing M&A, equity prices and debt financings
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)
Young & Partners covers the changes the chemical industry is facing now and will face in the future
Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)
Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook